新型糖尿病治疗药物exendin-4的研究进展  

Recent progress on exendin-4,a novel therapeutic drug for diabetes

作　　者：宋光明[1] 申竹芳[1] 

机构地区：[1]中国医学科学院、北京协和医学院药物研究所,北京100050

出　　处：《中国临床药理学杂志》2008年第2期156-160,共5页The Chinese Journal of Clinical Pharmacology

摘　　要：Exendin-4(降血糖药)是首个在美国获准上市用于治疗2型糖尿病的肠促胰岛素拟似物。临床研究表明,其与二甲双胍、磺酰脲类药物、或噻唑烷二酮类药物合用,能有效地控制2型糖尿病患者的血糖。Exendin-4的作用机制包括葡萄糖依赖的促胰岛素分泌、抑制胰高血糖素分泌、增加β细胞质量、减缓胃排空和抑制食欲。近来还发现,exendin-4可增加胰岛移植受者的胰岛素分泌量。Exendin-4对中枢神经系统也有保护作用。本文对ex-endin-4的药理作用及其机制、药物特点等作一综述。Exendin -4 is the first approved drug in the incretin mimetic class and is indicated for treatment of type 2 diabetes mellitus. Randomized trials have shown exendin- 4 to be efficacious in improving glycemic control when combined with either mefformin, a sulfonylurea, or a thiazolidinedione. Evidence suggests that the agent mechanisms may include glucose - dependent stimulation of insulin secretion, suppression of glucagon secretion, enhancement of β cell mass, slowing of gastric emptying and inhibition of food intake. Exendin -4 stimulates insulin secretion in islet transplant recipients. Last studies illustrate a potential protective role for exendin -4 in the central nervous systems. The article mainly reviews the pharmacological efficacy and its mechanisms of exendin -4, and contrasts exendin -4 actions with other antidiabetics.

关 键 词：EXENDIN-4 肠促胰岛素拟似物 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌] R977.15[医药卫生—内科学]